Gilead dumps late-stage colitis program after failing to find benefit

Gilead ($GILD) said in a brief update that it will be canning its combined Phase II/III test of its experimental GI med GS-5745 after finding that there was “insufficient evidence of a treatment benefit” in those taking the drug.

The med, an anti-MMP9 antibody, was being used to treat patients with active ulcerative colitis, but failed to make the grade.

But the drug will live on in its ongoing Phase III test in patients with gastric cancer, as well as a midstage combo study with Bristol-Myers ($BMY) checkpoint inhibitor Opdivo (nivolumab).

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

It is also not cutting its GI hopes completely with the med, as a Phase II in moderately to severely active Crohn's disease is still going ahead--as well as other tests in rheumatoid arthritis and cystic fibrosis. “These studies will continue as planned,” Gilead said.

The California company fell by 0.10% at the end of yesterday, but was up by the same amount premarket this morning.

The $111 billion market cap Big Biotech has been at the center of increasing speculation that it will make a big buy with its cash pile from its major blockbuster hep C sales over the past few years--but a big deal has yet to materialize.

Rumors have also started this week that the highly acquisitive Allergan ($AGN) may be looking to buy Gilead, although Allergan’s current market cap is around $16 billion less that its alleged target.

It’s not the first time Gilead has run into trial trouble. Earlier this year it halted 6 trials of its oncology med Zydelig (idelalisib) for first-line use in blood cancers after reports of serious side effects--including multiple deaths--among participants in several of the studies.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.